1. Home
  2. VET vs MLYS Comparison

VET vs MLYS Comparison

Compare VET & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$11.06

Market Cap

2.0B

Sector

Energy

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.83

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VET
MLYS
Founded
1994
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2004
2023

Fundamental Metrics

Financial Performance
Metric
VET
MLYS
Price
$11.06
$23.83
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$15.00
$48.67
AVG Volume (30 Days)
1.0M
1.7M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
2.84%
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.07
N/A
Revenue Next Year
$3.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$12.59
52 Week High
$14.82
$47.65

Technical Indicators

Market Signals
Indicator
VET
MLYS
Relative Strength Index (RSI) 38.48 37.56
Support Level $10.20 $22.42
Resistance Level $12.00 $31.29
Average True Range (ATR) 0.42 1.70
MACD -0.06 -0.78
Stochastic Oscillator 4.96 17.38

Price Performance

Historical Comparison
VET
MLYS

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: